The COVID-19 Adverse Event Dashboard

by | Mar 24, 2021 | COVID-19, FDA, Medical Devices, Pharma, Quality, Real World Evidence, Regulatory

The FDA’s adverse event reporting system (FAERS) is a web-based tool that allows users to interactively search and query adverse event data. The tool intends to provide users access to adverse event reports submitted by the pharmaceutical industry, health care practitioners, and consumers.1

As the number of drugs and biologics authorized under the COVID-19 EUA umbrella is increasing, FDA realized the need to capture information for COVID-19 emergency use authorization products. The COVID-19 EUA FAERS public dashboard updates weekly with adverse events related to drugs and biologics authorized to be marketed under the COVID-19 EUA.1

While FAERS is a helpful tool to provide information about adverse events reported to the FDA, there are certain limitations to this data:1

  • While the FAERS reports contain information about the usage of the drug or biologic it does not necessarily mean that the drug or biologic caused the adverse event. The event may have been caused by underlying diseases, comorbidities, or some other drug.
  • There may be duplicate or incomplete reports in the system and may not provide all the required information.
  • The information submitted in these reports has not been verified by any health care agency or medical experts.
  • These reports cannot be used to establish incidence or occurrence rates.

Users should also note that the data in FAERS is not an indicator of the safety profile of the drug or biologic.  The data uploaded to the FAERS is important to the FDA to look for new safety concerns, evaluate the manufacturer’s compliance with the regulations, etc. These reports are also evaluated by FDA’s clinical reviewers for trends that help the Agency to take appropriate actions such as inspections and other types of enforcements.1

The FAERS is a step towards FDA’s initiative to collect real-world evidence and use it for monitoring purposes. I strongly believe that initiatives such as the NEST program (National Evaluation System for Health Technology) will further advance this effort and allow for more evidence-based decision-making. EMMA International is here to help you with all your quality and regulatory needs. Call us today at 248-987-4497 or email us at to find out more.

1FDA (2021) FDA Adverse Event Reporting System (FAERS) Public Dashboard retrieved on 03/20/2021 from

Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This